Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study

Journal of Affective Disorders

Volumn 112, Issue 1-3, 2009, Pages 36-49

  Keck, P E ^a   Orsulak, P J ^b,c   Cutler, A J ^d   Sanchez, R ^e   Torbeyns, A ^f   Marcus, R N ^f   McQuade, R D ^e   Carson, W H ^e  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

Atypical; Bipolar disorder; Mood; Stabilizer

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; LITHIUM; LORAZEPAM; PLACEBO; PROPRANOLOL;

ADULT; AGED; AKATHISIA; ARTICLE; BIPOLAR I DISORDER; BIPOLAR MANIA; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; TREATMENT RESPONSE; TREMOR;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEADACHE; HUMANS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; NAUSEA; PIPERAZINES; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 56549122054     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2008.05.014     Document Type: Article

References (34)

1. APA. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (2000) Text Revision, Washington, DC
2. APA. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry 159 (2002) 1-50
3. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989) 672-676
4. Bowden C.L., Grunze H., Mullen J., Brecher M., Paulsson B., Jones M., Vagero M., and Svensson K. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiatry 66 (2005) 111-121
5. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., and Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302 (2002) 381-389
6. Fagiolini A., Frank E., Scott J.A., Turkin S., and Kupfer D.J. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar. Disord. 7 (2005) 424-430
7. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338 (1976), National Institute of Mental Health, Rockville, MD 534-537
8. Hirschfeld R., Keck P.J., Kramer M., Karcher K., Canuso C., Eerdekens M., and Grossman F. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am. J. Psychiatry 161 (2004) 1057-1065
9. Kay S.R., Fiszbein A., and Opler L.A. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
10. Keck P.E., Calabrese J.R., McIntyre R.S., McQuade R.D., Carson W.H., Eudicone J.M., Carlson B.X., Marcus R.N., and Sanchez R. Aripiprazole monotherapy for maintaining efficacy in bipolar I disorder: a 100-week, double-blind study versus placebo. J. Clin. Psychiatry 68 (2007) 1480-1491
11. Keck P.E., Calabrese J.R., McQuade R.D., Carson W.H., Carlson B.X., Rollin L.M., Marcus R.N., and Sanchez R. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry 67 (2006) 626-637
12. Keck Jr. P.E., Marcus R., Tourkodimitris S., Ali M., Liebeskind A., Saha A., and Ingenito G. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry 160 (2003) 1651-1658
13. Keck P.J., Versiani M., Potkin S., West S., Giller E., Ice K., and Group Z.i.M.S. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am. J. Psychiatry 160 (2003) 741-748
14. Khanna S., Vieta E., Lyons B., Grossman F., Eerdekens M., and Kramer M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br. J. Psychiatry 187 (2005) 229-234
15. McElroy S.L., Kotwal R., Malhotra S., Nelson E.B., Keck P.E., and Nemeroff C.B. Are mood disorders and obesity related? A review for the mental health professional. J. Clin. Psychiatry 65 (2004) 634-651 quiz 730
16. McIntyre R.S., Brecher M., Paulsson B., Huizar K., and Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania: a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur. Neuropsychopharmacol. 15 (2005) 573-585
17. McIntyre R.S., Konarski J.Z., Wilkins K., Soczynska J.K., and Kennedy S.H. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can. J. Psychiatry 51 (2006) 274-280
18. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979) 382-389
19. Niufan G., Tohen M., Qiuqing A., Fude Y., Pope E., McElroy H., Ming L., Gaohua W., Xinbao Z., Huichun L., and Liang S. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J. Affect. Disord. 105 (2008) 101-108
20. Potkin S.G., Keck Jr. P.E., Segal S., Ice K., and English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J. Clin. Psychopharmacol. 25 (2005) 301-310
21. Sachs G., Sanchez R., Marcus R., Stock E., McQuade R., Carson W., Abou-Gharbia N., Impellizzeri C., Kaplita S., Rollin L., and Iwamoto T. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J. Psychopharmacol. 20 (2006) 536-546
22. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., and Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411
23. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., and Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59 (1998) 22-33 quiz 34-57
24. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand., Suppl. 212 (1970) 11-19
25. Smulevich A.B., Khanna S., Eerdekens M., Karcher K., Kramer M., and Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur. Neuropsychopharmacol. 15 (2005) 75-84
26. Suppes T., Dennehy E.B., Hirschfeld R.M., Altshuler L.L., Bowden C.L., Calabrese J.R., Crismon M.L., Ketter T.A., Sachs G.S., and Swann A.C. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry 66 (2005) 870-886
27. Tohen M., Goldberg J.F., Gonzalez-Pinto Arrillaga A.M., Azorin J.M., Vieta E., Hardy-Bayle M.C., Lawson W.B., Emsley R.A., Zhang F., Baker R.W., Risser R.C., Namjoshi M.A., Evans A.R., and Breier A. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch. Gen. Psychiatry 60 (2003) 1218-1226
28. Tohen M., Jacobs T.G., Grundy S.L., McElroy S.L., Banov M.C., Janicak P.G., Sanger T., Risser R., Zhang F., Toma V., Francis J., Tollefson G.D., and Breier A. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch. Gen. Psychiatry 57 (2000) 841-849
29. Tohen M., Sanger T.M., McElroy S.L., Tollefson G.D., Chengappa K.N., Daniel D.G., Petty F., Centorrino F., Wang R., Grundy S.L., Greaney M.G., Jacobs T.G., David S.R., and Toma V. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am. J. Psychiatry 156 (1999) 702-709
30. Vieta E., Bourin M., Sanchez R., Marcus R., Stock E., McQuade R.D., Carson W., Abou-Gharbia N., Swanink R., Iwamoto T., and on behalf of the Aripiprazole Study Group. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br. J. Psychiatry 187 (2005) 235-242
31. Vieta E., and Carne X. The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychother. Psychosom. 74 (2005) 10-16
32. Vieta E., Mullen J., Brecher M., Paulsson B., and Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr. Med. Res. Opin. 21 (2005) 923-934
33. White L., Harvey P.D., Opler L., and Lindenmayer J.P. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology 30 (1997) 263-274
34. Young R.C., Biggs J.T., Ziegler V.E., and Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133 (1978) 429-435